The 2018 Lebanese Society of Infectious Diseases and Clinical Microbiology Guidelines for the use of antimicrobial therapy in complicated intra-abdominal infections in the era of antimicrobial resistance

dc.contributor.authorHaddad, Nicholas
dc.contributor.authorKanj, Souha S.
dc.contributor.authorAwad, Lyn S.
dc.contributor.authorAbdallah, Dania Issam
dc.contributor.authorMoghnieh, Rima A.
dc.contributor.departmentInternal Medicine
dc.contributor.departmentDivision of Infectious Diseases
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T11:54:58Z
dc.date.available2025-01-24T11:54:58Z
dc.date.issued2019
dc.description.abstractBackground: The Lebanese Society of Infectious Diseases and Clinical Microbiology (LSIDCM) is involved in antimicrobial stewardship. In an attempt at guiding clinicians across Lebanon in regards to the proper use of antimicrobial agents, members of this society are in the process of preparing national guidelines for common infectious diseases, among which are the guidelines for empiric and targeted antimicrobial therapy of complicated intra-abdominal infections (cIAI). The aims of these guidelines are optimizing patient care based on evidence-based literature and local antimicrobial susceptibility data, together with limiting the inappropriate use of antimicrobials thus decreasing the emergence of antimicrobial resistance (AMR) and curtailing on other adverse outcomes. Methods: Recommendations in these guidelines are adapted from other international guidelines but modeled based on locally derived susceptibility data and on the availability of pharmaceutical and other resources. Results: These guidelines propose antimicrobial therapy of cIAI in adults based on risk factors, site of acquisition of infection, and clinical severity of illness. We recommend using antibiotic therapy targeting third-generation cephalosporin (3GC)-resistant gram negative organisms, with carbapenem sparing as much as possible, for community-acquired infections when the following risk factors exist: prior (within 90 days) exposure to antibiotics, immunocompromised state, recent history of hospitalization or of surgery and invasive procedure all within the preceding 90 days. We also recommend antimicrobial de-escalation strategy after culture results. Prompt and adequate antimicrobial therapy for cIAI reduces morbidity and mortality; however, the duration of therapy should be limited to no more than 4 days when adequate source control is achieved and the patient is clinically stable. The management of acute pancreatitis is conservative, with a role for antibiotic therapy only in specific situations and after microbiological diagnosis. The use of broad-spectrum antimicrobial agents including systemic antifungals and newly approved antibiotics is preferably restricted to infectious diseases specialists. Conclusion: These guidelines represent a major step towards initiating a Lebanese national antimicrobial stewardship program. The LSIDCM emphasizes on development of a national AMR surveillance network, in addition to a national antibiogram for cIAI stratified based on the setting (community, hospital, unit-based) that should be frequently updated. © 2019 The Author(s).
dc.identifier.doihttps://doi.org/10.1186/s12879-019-3829-2
dc.identifier.eid2-s2.0-85063724236
dc.identifier.pmid30925909
dc.identifier.urihttp://hdl.handle.net/10938/31182
dc.language.isoen
dc.publisherBioMed Central Ltd.
dc.relation.ispartofBMC Infectious Diseases
dc.sourceScopus
dc.subjectAntimicrobial resistance
dc.subjectAntimicrobial stewardship
dc.subjectAntimicrobial therapy
dc.subjectComplicated intra-abdominal infections
dc.subjectGuidelines
dc.subjectLebanon
dc.subjectAdult
dc.subjectAnti-infective agents
dc.subjectCommunity-acquired infections
dc.subjectDrug resistance, microbial
dc.subjectHumans
dc.subjectImmunocompromised host
dc.subjectIntraabdominal infections
dc.subjectMicrobial sensitivity tests
dc.subjectPancreatitis
dc.subjectTime factors
dc.subjectAminoglycoside antibiotic agent
dc.subjectAntifungal agent
dc.subjectAntiinfective agent
dc.subjectBeta lactam antibiotic
dc.subjectBeta lactamase inhibitor
dc.subjectCarbapenem
dc.subjectCephalosporin derivative
dc.subjectCorticosteroid
dc.subjectEchinocandin
dc.subjectGlycylcycline derivative
dc.subjectImipenem
dc.subjectMeropenem
dc.subjectMetronidazole
dc.subjectOxazolidinone derivative
dc.subjectPiperacillin plus tazobactam
dc.subjectPolymyxin
dc.subjectPolypeptide antibiotic agent
dc.subjectQuinoline derived antiinfective agent
dc.subjectAbdominal infection
dc.subjectAcinetobacter baumannii
dc.subjectAcute pancreatitis
dc.subjectAdverse outcome
dc.subjectAntibiotic resistance
dc.subjectAntibiotic sensitivity
dc.subjectApache
dc.subjectArticle
dc.subjectBiliary tract infection
dc.subjectBiochemical analysis
dc.subjectCandida
dc.subjectCholangitis
dc.subjectCommunity acquired infection
dc.subjectComputer assisted tomography
dc.subjectDisease classification
dc.subjectDisease severity
dc.subjectDrug exposure
dc.subjectEscherichia coli
dc.subjectEvidence based practice
dc.subjectHospitalization
dc.subjectHuman
dc.subjectImmunocompromised patient
dc.subjectInappropriate prescribing
dc.subjectInfection risk
dc.subjectInvasive procedure
dc.subjectKlebsiella
dc.subjectMagnetic resonance cholangiopancreatography
dc.subjectMicrobiological examination
dc.subjectMorbidity
dc.subjectMortality rate
dc.subjectNonhuman
dc.subjectPatient care
dc.subjectPatient history of surgery
dc.subjectPeritonitis
dc.subjectPractice guideline
dc.subjectPseudomonas aeruginosa
dc.subjectSeptic shock
dc.subjectTreatment duration
dc.subjectMicrobial sensitivity test
dc.subjectMicrobiology
dc.subjectTime factor
dc.titleThe 2018 Lebanese Society of Infectious Diseases and Clinical Microbiology Guidelines for the use of antimicrobial therapy in complicated intra-abdominal infections in the era of antimicrobial resistance
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2019-7565.pdf
Size:
733.53 KB
Format:
Adobe Portable Document Format